Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it has been selected for an oral presentation of its long-term icovamenib follow up data at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place in Los Angeles, California on December 3-6, 2025. The Congress showcases cutting-edge developments from both emerging investigators and world-renowned leaders.

"We are delighted to present our Week 52 long-term follow up data at WCIRDC, a meeting renowned for showcasing exciting advances in diabetes and metabolic research," said Mick Hitchcock, Ph.D., Interim CEO and Board Member of Biomea Fusion. "Being one of only six oral presentations this year speaks to the interest in icovamenib as a potential paradigm shift in the treatment of type 2 diabetes. Insulin-deficient diabetes remains an underserved population with limited therapeutic options, and icovamenib is potentially a novel treatment option for these patients."

Oral Presentation Abstract #0062
COVALENT-111: Durable Glycemic and C-Peptide Improvements with Icovamenib, a Menin Inhibitor Targeting β-Cell Restoration in Insulin-Deficient Type 2 Diabetes
Presentation Time
Oral Presentation: December 5, 2025, from 6:15 pm – 7:45 pm PST

Please find a link here to our website where the poster and presentations will be available.

About Icovamenib
Icovamenib is an investigational, orally bioavailable, potent, and selective covalent inhibitor of menin. The proposed mechanism of action for icovamenib in diabetes is selective and partial inhibition of menin, a regulator of beta cell quantity and function, thereby enabling the proliferation, preservation, and reactivation of a patient's own healthy, functional, insulin-producing beta cells. As the first non-chronic therapy for T2D, icovamenib could become an important addition to the diabetes treatment landscape once it has successfully completed its ongoing clinical studies.

About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world's population. Biomea's mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.

Visit us at www.biomeafusion.com and follow us on LinkedIn , X and Facebook .

Contact:
Meichiel Jennifer Weiss
Sr. Director of Investor Relations and Corporate Development
ir@biomeafusion.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

BMEA:US
The Conversation (0)
Steadright Signs Facilitator Agreement To Negotiate Critical Minerals Deal In Morocco

Steadright Signs Facilitator Agreement To Negotiate Critical Minerals Deal In Morocco

(TheNewswire) Muskoka, Ontario November 19th, 2026 TheNewswire Steadright Critical Minerals Inc. (CSE: SCM) ("Steadright" or the "Company") is pleased to announce that it has entered into a Share Acquisition Facilitation and Funding Agreement dated November 13, 2026 (the "Agreement") with... Keep Reading...
Ni-Co Energy Reports 4.60 Metres at 0.59% Nickel at Kremer-2; Phase-One Drilling Advances Magmatic Sulphide Exploration Model

Ni-Co Energy Reports 4.60 Metres at 0.59% Nickel at Kremer-2; Phase-One Drilling Advances Magmatic Sulphide Exploration Model

Assay-confirmed shallow mineralization; Sulphide-bearing mafic rocks at depth; Spring 2027 drilling planned Ni-Co Energy Inc. (TSXV: NICE,OTC:NICLF) ("Ni-Co" or the "Company") reports results from the initial phase of its 2026 diamond drilling campaign at its 100%-owned Kremer... Keep Reading...
Metalsource Mining Inc.    Reports New Drill Holes, Bold Exploration Push at Historic Silver Mine

Metalsource Mining Inc. Reports New Drill Holes, Bold Exploration Push at Historic Silver Mine

Via MiningNewsWire — Metalsource Mining Inc. (CSE: MSM) (OTCQB: MSMMF) (FSE: E9Z) today announces its placement in an editorial published by via MiningNewsWire ("MNW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a... Keep Reading...
Metalsource Mining Receives $1.38 Million from Eric Sprott Warrant Exercise as Silver Hill Gold-Silver Exploration Advances

Metalsource Mining Receives $1.38 Million from Eric Sprott Warrant Exercise as Silver Hill Gold-Silver Exploration Advances

Eric Sprott now holds approximately 19.9% of outstanding shares, as proceeds strengthen Metalsource's treasury to advance aggressive expansion drilling and larger stepouts investigating the potential scale of the Silver Hill polymetallic system in North Carolina.Metalsource Mining Inc. (CSE:... Keep Reading...
America May Be Sitting on a Gold and Silver Fortune Hiding in Plain Sight

America May Be Sitting on a Gold and Silver Fortune Hiding in Plain Sight

MiningNewsWire Editorial Coverage: With U.S. debt climbing above 100% of GDP while central banks are still accumulating gold, investors are once again seeking safety in silver and gold. Zinc, lead, copper and silver, meanwhile, all now appear on the 2025 List of Critical Minerals published by... Keep Reading...
Eric Sprott Announces Changes to His Holdings in Metalsource Mining Inc.

Eric Sprott Announces Changes to His Holdings in Metalsource Mining Inc.

Eric Sprott announces that on November 17, 2026, 2176423 Ontario Ltd. (a corporation he beneficially owns) exercised 3,750,000 common share purchase warrants (Warrants) of Metalsource Mining Inc., at $0.30 per common share (Share) and 637,158 Warrants at $0.40 per Share for aggregate... Keep Reading...

Interactive Chart

Latest Press Releases

Related News